# Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

> **NCT01871441** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 4 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **RADIATION:** Total-body irradiation
- **BIOLOGICAL:** Donor lymphocytes infusion (DLI)
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplantation (HSCT)
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT01871441
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-17
- **Primary completion:** 2013-12-12
- **Final completion:** 2016-10-20
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Trial was closed due to poor accrual.
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871441, "Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01871441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*